Advancing the future of medicine
Like you, we are eager to touch down in San Diego for the BIO convention.
Together, let’s explore the possibilities for manufacturing new biologics.
Discover how Cytiva supports the rapidly changing biopharma ecosystem and the ever-advancing future of medicine.
Speed. Innovation. Efficiency.
Whatever your strategy, let’s combine our strengths with yours to bring better medicines to life.
Let’s talk at Booth #1025.
Creating a resilient industry together
Learning through a global pandemic, biopharma is evolving to embrace innovations that could unlock the next wave of diagnostics, vaccines, and medicines.
In collaboration with Longitude, a Financial Times company, Cytiva has developed the Global Biopharma Resilience Index. This index uses survey response data to rank biopharma capabilities and resilience in 20 countries, scoring each on five factors critical to meeting global demand during a public health crisis.
These five actions have emerged as key areas of development that will help pharma and biopharma industries to continue taking giant steps towards securing the resilience of pharmaceutical manufacturing throughout the global health system – marking the achievements of 2020 and preparing for the future.
Within these five pillars of advancement, we can envision a world in which access to the latest biologics transforms health.
Not yet registered for BIO International 2022? Find out more now!
Talent management
The biopharmaceutical industry depends on a strong pipeline of specialist skills. Yet more than 50% of executives and policymakers say that the rising cost of talent has become increasingly difficult.
We can help with access to purpose-built institutions replicating modern bioprocessing and cell and gene facilities for training and services.
View Cytiva collaboration centers
R&D collaboration
Strategic relationships help the industry evolve. Entities that nurture their R&D, education, and infrastructure investments are a step ahead, and collaboration will be key to driving a vibrant R&D ecosystem. But just 44% of executives and policymakers believe a widespread culture of cooperation exists in the industry. We can do better.
Our global Fast Trak™ team delivers high-quality scientific insights, increased proficiency in technical skills, and robust solutions to your challenges in process development and manufacturing. Work with us to gain confidence at every stage of the development process.
Explore Fast Trak™ Bioprocessing Solutions
Manufacturing agility
To respond to capacity needs and establish agile manufacturing practices, we must: deploy manufacturing processes to rapidly scale operations with continuous manufacturing methods; adopt bold technologies; and ensure reproducible results.
However, executives and policymakers report that they can meet only 74% of domestic need for critical medications.
Supply chain resilience
Government policy effectiveness
To deliver new drugs more quickly, biopharma must work in harmony with governments and regulators to accelerate regulatory pathways where appropriate.
With 65% of executives reporting that their countries are instigating tax or trade policies that help domestic production and R&D, we must work in harmony to improve clarity and collaboration to achieve industry-wide goals.
Collaborate on biomanufacturing capacity
LinkedIn Live broadcast
BIO International 2022
San Diego Convention Center
San Diego, CA
Privacy | Terms | Trademarks | Legal | Contact
© 2022 Cytiva